Mon, March 4, 2013
Sun, March 3, 2013
Sat, March 2, 2013
Fri, March 1, 2013
Thu, February 28, 2013
Wed, February 27, 2013
Tue, February 26, 2013
Mon, February 25, 2013
Sun, February 24, 2013
Sat, February 23, 2013
Fri, February 22, 2013
Thu, February 21, 2013
[ Thu, Feb 21st 2013 ] - Market Wire
Inorganic Growth of Healthcare
Wed, February 20, 2013
Tue, February 19, 2013
Mon, February 18, 2013
Sun, February 17, 2013
Fri, February 15, 2013
Thu, February 14, 2013
Wed, February 13, 2013
Tue, February 12, 2013
Mon, February 11, 2013
Sun, February 10, 2013
Fri, February 8, 2013

Sarepta Therapeutics to Present at Cowen &;; Company 33rd Annual Healthcare Conference


//health-fitness.news-articles.net/content/2013/ .. 9-company-33rd-annual-healthcare-conference.html
Published in Health and Fitness on by Market Wire   Print publication without navigation


February 21, 2013 08:30 ET

Sarepta Therapeutics to Present at Cowen & Company 33rd Annual Healthcare Conference

Webcast Accessible via Sarepta Therapeutics Website

CAMBRIDGE, MA--(Marketwire - Feb 21, 2013) -  Sarepta Therapeutics (NASDAQ: [ SRPT ]), a developer of innovative RNA-based therapeutics, announced today that it is scheduled to present at the Cowen 33rd Annual Healthcare Conference in Boston, MA on March 4 at 2:50pm EST. Chris Garabedian, Sarepta's President and CEO, will be presenting a company overview.

The presentation will be webcast live under the events section of Sarepta Therapeutics' website at [ www.sareptatherapeutics.com ] and will be archived there following the presentation for 90 days. Please connect to Sarepta's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.

About Sarepta Therapeutics

Sarepta Therapeutics is focused on developing first-in-class RNA-based therapeutics to improve and save the lives of people affected by serious and life-threatening rare and infectious diseases. The Company's diverse pipeline includes its lead program eteplirsen, for Duchenne muscular dystrophy, as well as potential treatments for some of the world's most lethal infectious diseases. Sarepta aims to build a leading, independent biotech company dedicated to translating its RNA-based science into transformational therapeutics for patients who face significant unmet medical needs. For more information, please visit us at [ www.sareptatherapeutics.com ].



Publication Contributing Sources